Private Biotech Innovation Summit "Neuro momentum continues, women's hea..."

Research evidence excerpt

Private Biotech Innovation Summit "Neuro momentum continues, women's hea..."

Global Research

22 May 2026ab

Private Biotech Innovation Summit Equities

AmericasNeuro momentum continues, women's health

gaining traction Biotechnology

Samantha Meadows, PhD

Analyst

samantha.meadows@ubs.com

Near term biotech investor focus remains on clinically de-risked pipeline assets +1-212-713 2482

over platform, though we see AI as a potential longer-term platform value

Angela Kumirai

generator.

Associate Analyst

We hosted 30+ companies at our Biotech Private Company Symposium (see profiles of angela.kumirai@ubs.com

attending companies here and here). Overall, we thought that sentiment was upbeat, +1-212-713 1266

particularly given the robust M&A and IPO activity we have seen YTD (see inside for

detailed figures). We continue to view psychedelics as a catalyst rich space and an area

we think we could see growing strategic interest over the coming 1-2 yrs.

Our corporate VC panelists highlighted Superluminal Medicines (biotech developing

small molecules for cardiometabolic disease) and Zag Bio when we asked about a

portfolio company they thought the audience should be aware of. We profile

Superluminal Medicines and Zag Bio inside the report.

Below we outline our key takes from the conference:

Investors cautious on AI platforms: Across biotech, but particularly for AI drug

discovery companies, investor conviction is driven by clinical progress and assets,

not platform value. We think the bar to get conviction around a platform is high,

and we think value is better realized near-term through execution on a diversified

pipeline. However, we see potential acceleration of value accretion for companies

with AI platforms that become more efficient and reliable with more data.